Mikihiko NaitoChief, Division of Molecular

Target and Gene Therapy ProductsNational Institute of

Health Sciences

Gwenn M. HansenVice President

Drug Discovery TechnologiesNurix Therapeutics

Behnam NabetResearch Fellow

Dana-Farber Cancer Institute

Masato KanemakiProfessor

National Institute of Genetics

Yusuke TominariCEO/CSO

Co-FounderFIMECS, Inc.

Hyunsun JoFounder and CEO

Pin Therapeutics, Inc.

Michael PleweVice President-

Medicinal ChemistryCullgen Inc.

Kanae GamoVP Biology

Co-FounderFIMECS, Inc.

Hirokazu ArimotoProfessor

Graduate School of LifeSciences

Tohoku University

Takumi ItoAssociate Professor

Department of NanoparticleTranslational Research

Tokyo Medical University

Taisuke UeharaPrincipal Scientist

Eisai Co., Ltd.

SPEAKERS

Targeted Protein Degradation Forum in Japan

REGISTRATION FEE

From July 20,2019Payment received

Industry JPY 50,000

JPY 40,000Academia・iPark tenant

https://www.ibtool.biz/tpd-forum/

Registration

Targeted Protein Degradation Forum in Japan （ibma,Co.,Ltd） / Mail:summit@ibtool.jp

Contact

August 22-23, 2019

10:30~18:30 ( Session+Exhibition )18:30~20:00 ( Dinner party )

Day-1

10:00~15:00 ( Session+Exhibition )15:00~18:00 ( Partnering+Exhibition )

Day-2

At Shonan iPark

( Full package: Conference, Lunch, Dinner, iPark tour, Partnering )

https://www.shonan-health-innovation-park.com/siteassets/pdfs/180510access-en.pdf

Targeted Protein Degradation (TPD) is emerging technology. TPD is well known as Proteolysis Targeting Chimeras (PROTACs), the bi-functional molecules composed

target binder with E3 ligase binder to hijack ubiquitin-proteasome system (UPS). In addition, Molecular Glue also lead to degrade the targeted proteins. Unlike

conventional inhibitors, TPD has a potential to achieve the Drugging Undruggable Targets. Arvinas announced the initiation of first clinical trials of PROTACs drugs in

this year. Now, researchers around the world are interested in TPD area. Therefore, this is very attractive event in terms of the deep discussion, networking with

KOLs and business partnering among Academia, Pharma and service providers.

DESCRIPTION

PROGRAM

GOLD Sponsors

DAY-1 [8/22] DAY-2 [8/23]

Registration9:30 Registration9:00

Opening remarks10:30~10:45

Key note : Induced protein degradation by chimeric small molecules; recent progress and outlook10:45~11:30

Chief, Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences

Mikihiko Naito

Key note : TBD10:00~10:45 Vice President Drug Discovery Technologies

Nurix TherapeuticsGwenn M. Hansen

Presentation : Sulfonamide Small Molecules Target DCAF15-CUL4 Ubiquitin Ligase to Promote Selective Degradation of Splicing Factor CAPER-alpha10:45~11:15

Principal Scientist Eisai Co., Ltd.Taisuke Uehara

Presentation : Molecular mechanisms of cereblon-based drugs11:15~11:45

Associate Professor Department of Nanoparticle Translational Research Tokyo Medical University

Takumi Ito

Luncheon seminar : TBD12:00~12:30 WuXi AppTec

Networking break12:30~13:00

Key note : Ubiquitin mediated small molecule induced target elimination (uSMITE) for cancer13:00~13:30

Vice President - Medicinal Chemistry Cullgen Inc.Michael Plewe

Key note : Targeted IRAK-M degradation as a novel approach in cancer immunotherapy overcoming innate-driven immunosuppression13:30~14:00

VP Biology Co-Founder FIMECS, Inc.Kanae Gamo

Panel discussion14:00~14:45

Closing remarks14:45~14:55

Partnering15:00~18:00

Presentation : RaPPIDS : E�cient discovery platform of the targeted protein degradation drugs11:30~12:00

CEO/CSO, Co-Founder FIMECS, Inc.Yusuke Tominari

iPark company session : Hit compound identification for any target by high-throughput binding screening12:00~12:15SEED SUPPLY Inc.

Luncheon seminar : Protein Degradation as an emerging approach for targeting kinomeCarna Biosciences,Inc.

Networking break

12:30~13:00

13:00~13:30

Presentation : Landscaping di�erent E3 ligases as a platform of protein degradation therapeutics13:30~14:00

Founder and CEO Pin Therapeutics, Inc.Hyunsun Jo

Presentation : Autophagy-based targeted degradation14:00~14:30

Professor Graduate School of Life Sciences Tohoku University

Hirokazu Arimoto

PresentationComing soon14:30~15:00

Networking break15:00~15:30

Keynote : Leveraging the dTAG platform to degrade cancer dependencies15:30~16:00

Research Fellow Dana-Farber Cancer InstituteBehnam Nabet

Key note : The Auxin-Inducible-Degron System as a Tool for Target Validation16:00~16:30

Professor National Institute of GeneticsMasato Kanemaki

Networking break16:30~17:00

iPark company session : Introduction of Axcelead17:00~17:15Axcelead Drug Discovery Partners, Inc.

iPark tour17:15~18:30 iPark / Axcelead Drug Discovery

Partners, Inc.

Dinner party18:30~20:00

Sponsors

Event Par tner